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Abstract: 
 
Background: Pancreatic cancer is one of the cancers where anti-PD-L1/PD-1 immunotherapy 
has been unsuccessful. What confers pancreatic cancer resistance to checkpoint immunotherapy 
is unknown. The aim of this study is to elucidate the underlying mechanism of PD-L1 expression 
regulation in the context of pancreatic cancer immune evasion. 
 
Methods: Pancreatic cancer mouse models and human specimens were used to determine PD-L1 
and PD-1 expression and cancer immune evasion. Histone methyltransferase inhibitors, RNAi, 
and overexpression were used to elucidate the underlying molecular mechanism of PD-L1 
expression regulation. All statistical tests were two-sided. 
 
Results: PD-L1 is expressed in 60% to 90% of tumor cells in human pancreatic carcinomas and 
in nine of 10 human pancreatic cancer cell lines. PD-1 is expressed in 51.2% to 52.1% of 
pancreatic tumor–infiltrating cytotoxic T lymphocytes (CTLs). Tumors grow statistically 
significantly faster in FasL-deficient mice than in wild-type mice (P = .03–.001) and when CTLs 
are neutralized (P = .03–<.001). H3K4 trimethylation (H3K4me3) is enriched in 
the cd274 promoter in pancreatic tumor cells. MLL1 directly binds to the cd274promoter to 
catalyze H3K4me3 to activate PD-L1 transcription in tumor cells. Inhibition or silencing of 
MLL1 decreases the H3K4me3 level in the cd274promoter and PD-L1 expression in tumor cells. 
Accordingly, inhibition of MLL1 in combination with anti-PD-L1 or anti-PD-1 antibody 
immunotherapy effectively suppresses pancreatic tumor growth in a FasL- and CTL-dependent 
manner. 
 
Conclusions: The Fas-FasL/CTLs and the MLL1-H3K4me3-PD-L1 axis play contrasting roles 
in pancreatic cancer immune surveillance and evasion. Targeting the MLL1-H3K4me3 axis is an 
effective approach to enhance the efficacy of checkpoint immunotherapy against pancreatic 
cancer. 
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Article: 
 
PD-1 is a T cell inhibitory receptor that interacts with its ligand PD-L1 to maintain self-tolerance 
and to protect against excessive tissue damage induced by immune responses, and thus functions 
as an immune checkpoint under physiological conditions (1). Under pathological conditions such 
as cancer, PD-L1 is often upregulated in tumor cells, resulting in potent immune suppression and 
tumor immune escape (2–8). Accordingly, blocking the interactions between PD-1 and PD-L1 
can induce durable efficacy of tumor suppression in both mouse tumor models and human cancer 
patients (9–13). However, human pancreatic cancer stands out as one cancer that does not 
respond to checkpoint immunotherapy (14). The mechanism underlying pancreatic cancer 
resistance to anti-PD-1/PD-L1 immunotherapy is unknown, but it has been suggested that the 
expression level of PD-L1 in tumor cells is a key determinant of checkpoint immunotherapy 
efficacy (9,15,16) 
 
PD-L1 is constitutively expressed and induced by inflammatory cytokines in the tumor 
microenvironment in human cancers (15,17,18). It has been reported that oncogenes such as 
AKT and STAT3 directly regulate constitutive PD-L1 expression in tumor cells (19,20). IFNγ is 
a proinflammatory cytokine secreted by activated T and natural killer (NK) cells and acts as an 
essential component of the host cancer immune surveillance system (21,22). However, IFNγ also 
acts as a master inducer of PD-L1 in tumor cells (16–18,23), suggesting that tumor cells may 
sense the elevated IFNγ as a “threat” in the tumor microenvironment and adapt it by upregulating 
PD-L1. These studies firmly established the role of oncogenes and inflammatory cytokines as 
key regulators of PD-L1 expression in tumor cells. We aimed at testing the hypothesis that PD-
L1 expression is regulated by an epigenetic mechanism in pancreatic cancer and epigenetic 
targeting of PD-L1 is an effective approach to enhance the efficacy of checkpoint 
immunotherapy for pancreatic cancer. 
 
Methods 
 
Cancer Cells 
 
Pancreatic, colon, and melanoma cancer cell lines were obtained from American Type Culture 
Collection (ATCC; Manassas, VA). ATCC has characterized these cells by morphology, 
immunology, DNA fingerprint, and cytogenetics. PANC02-H7 cells were kindly provided by Dr. 
Min Li (University of Oklahoma Health Sciences Center) and characterized as previously 
described (24,25). UN-KC-6141 cells were kindly provided by Dr. Surinder Batra (University of 
Nebraska Medical Center) and characterized as previously described (26). Human pancreatic 
cancer specimens were obtained from the Georgia Cancer Center tumor bank and from the 
Cooperative Human Tissue Network (CHTN) Southern Division. The tumor tissue specimens 
were analyzed by a board-certified pathologist. 
 
Orthotopic Mouse Pancreatic Cancer Models 
 
Six- to eight-week-old female WT C57BL/6 and faslgld mice were obtained from the Jackson 
Laboratory (Bar Harbor, ME). Mice were continuously anesthetized with isoflurane (1%–3% in 
oxygen). A small abdominal incision at the right side near the spleen was made, and the pancreas 
was identified with sterile gauze. Tumor cells (1x104 cells in 20 μL saline) were injected into the 
pancreas using a sterile tuberculin syringe. The abdomen was closed with wound clips. All 
mouse studies were performed according to protocols approved by Augusta University 
Institutional Animal Care and Use Committee. 
 
Statistical Analysis 
 
All statistical analysis was performed using SAS 9.4 (SAS Institute Inc., Cary, NC), and 
statistical significance was assessed using an alpha level of .05. Two-factor ANOVA was used to 
examine the interaction of treatments on tumor weight and volume within tumor cell type. A 
Tukey-Kramer multiple comparison procedure on the means of the interaction term was used to 
examine pair-wise post hoc differences between groups to control the overall statistical 
significance level. Two-sample t tests were used to determine differences in tumor weight and 
tumor volume between control and treatment groups or between WT C57BL/6 and faslgld mice. 
All statistical tests were two-sided. 
 
Additional methods are included in the Supplementary Methods and Supplementary Tables 1 and 
2 (available online). 
 
Results 
 
PD-L1 and PD-1 Expression Profiles in Pancreatic Tumor Cells and Pancreatic Tumor-
Infiltrating Cytotoxic T Lymphocytes 
 
To determine the expression profiles of PD-L1 and PD-1 in tumor-bearing mice, two orthotopic 
pancreatic carcinoma mouse models were established (Figure 1, A and E). Both PANC02-H7 
and UN-KC-6141 cells express PD-L1 in vitro, and the orthotopic tumor cells express 
statistically significantly higher levels of PD-L1 in in vivo than in in vitro cultured tumor cells 
(P < .001) (Figure 1, B and F). An average of 51.2% and 52.1% of tumor-infiltrating 
CD8+ cytotoxic T lymphocytes (CTLs) are PD-1+ in PANC02-H7 and UN-KC-6141 tumors, 
respectively (Figure 1, C, D, G, and H). An average of 6.82%, 4.16% and 3.76% CD8+ T cells in 
the spleen, lymph nodes (LNs), and peripheral blood, respectively, from the PANC02-H7 tumor-
bearing mice are PD-1+. Similarly, an average of 6.58%, 4.11%, and 33.3% of CD8+ T cells in 
the spleen, LNs, and peripheral blood, respectively, from the UN-KC-6141 tumor-bearing mice 
are PD-1+ (Figure 1, C D, G, and H). These data indicate that pancreatic cancer cells express 
elevated PD-L1 in vivo and pancreatic tumor–infiltrating CTLs express high levels of PD-1 in 
vivo in the tumor microenvironment.
 
 
Figure 1. PD-L1 and PD-1 expression profiles in pancreatic cancer in vivo. A) PANC02-H7 cells were surgically transplanted to 
pancreas of C57BL/6 mice to establish orthotopic pancreatic tumor (yellow arrow). B) PD-L1 expression level on cultured pancreatic 
cancer cells (in vitro) and the tumor (in vivo) as shown in (A). The PD-L1 protein level (mean fluorescent intensity [MFI]) was 
analyzed by two-sided ttest and presented at the right. Column: mean; bar: SD. C) Cell suspensions were prepared from pancreatic 
tumor tissues, spleen, LN, and peripheral blood from five tumor-bearing mice (n = 5) and stained with 7-AAD, CD8-, and PD-1-
specific antibodies. Stained cells were analyzed by flow cytometry. D) Quantification of CD8+PD-1+ CTLs in the indicated tissues. 7-
AAD+ dead cells were gated out. CD8+ cells were gated and analyzed for PD-1+ cells. E) UN-KC-6141 cells were surgically 
transplanted to the pancreas of C57BL/6 mice to establish orthotopic pancreatic tumor (yellow arrow). F) PD-L1 expression levels in 
cultured UN-KC-6141 cells (in vitro) and orthotopic UN-KC-6141 tumor (in vivo). The PD-L1 protein level (MFI) was analyzed by 
two-sided t test and presented at the right. Column: mean; bar: SD. G) Analysis of CD8+PD-1+ cells in the UN-KC-6141 tumor model 
in the indicated tissues. H) Quantification of CD8+PD-1+ CTLs in the indicated tissues. 7-AAD = 7-aminoactinomycin D; LN = lymph 
node; MFI = mean fluorescent intensity. 
 
 
Figure 2. Function of MLL1 in H3K4me3 regulation at the cd274 promoter and PD-L1 expression in tumor cells. A) The human 
CD274 (left panel) and mouse cd274 (right panel) gene promoter structures. B)Chromatin immunoprecipitation (ChIP) analysis of 
H3K4me3 levels in the CD274 promoter region in MiaPaca-2 cells. C) ChIP analysis of H3K4me3 levels in the cd274 promoter 
region in PANC02-H7 (left panel) and UN-KC-6141 (right panel) cells. D) ChIP analysis of H3K4me3 levels in the cd274 promoter 
region in normal mouse pancreatic tissues (left panel) and the orthotopic PANC02-H7 (middle panel) and UN-KC-6141 (right 
panel) tumor tissues, respectively. E) ChIP DNA fragments prepared as in (D) from normal mouse pancreas (n = 2: N1 and N2), the 
orthotopic PANC02-H7 tumors (n = 2: H1 and H2) and orthotopic UN-KC-6141 tumors (n = 2:U1 and U2) were cloned to construct 
DNA library and sequenced with a high-throughout sequencing system. The normalized sequence reads of H3K4me3 were mapped 
to cd274 gene region (-4000 of the 5’ regulatory region and the entire cd274gene) on mouse chromosome 19 (left panel). The -4000 
to + 1000 region relative to cd274transcription start site (+1) is shown at the right panel. F) C57BL/6 mouse pancreas (n = 3) and 
tumor tissues from PNAC02-H7 tumor-bearing (n = 3) and UN-KC-6141 tumor-bearing (n = 3) mice were analyzed by real-time 
polymerase chain reaction (top panel) for MLL1 and PD-L1 transcript levels and by immunoblotting (bottom panel) for MLL1 
protein level. G) ChIP analysis of MLL1 protein association with the cd274 promoter chromatin in PANC02-H7 cells (in vitro) and in 
orthotopic PANC02-H7 tumors (in vivo). H) MiaPaCa-2 cells were transiently transfected with scramble- and MLL1-specific siRNA, 
respectively, for 24 hours and analyzed for MLL1 mRNA level by quantitative polymerase chain reaction (qPCR), H3K4me3 level at 
the CD274 promoter region by ChIP (ChIP 4 as in (B)), and PD-L1 mRNA level by qPCR as indicated. I) PANC02-H7 cells were 
transiently transfected with scramble- and MLL1-specific siRNAs, respectively, for 24 hours and analyzed for MLL1 mRNA level by 
qPCR, H3K4me3 level in the cd274 promoter region by ChIP (ChIP 4 as in (C)), and PD-L1 mRNA level by qPCR as indicated. All 
statistical t tests were two-sided. ChIP = chromatin immunoprecipitation. 
MLL1-Mediated H3K4 Trimethylation in the CD274 Promoter Region and PD-L1 Expression 
 
In a screening for epigenetic mechanisms that regulate PD-L1 expression in pancreatic cancer 
cells, we observed enrichment of H3K4me3 marks in the proximal cd274 promoter region in 
both human (Figure 2, A and B) and mouse (Figure 2, A and C) pancreatic cancer cells cultured 
in vitro. Chromatin immunoprecipitation (ChIP) analysis revealed that H3K4me3 levels are 
enriched in the proximal cd274 promoter region in both PANC02-H7 and UN-KC-6141 
orthotopic tumors, whereas a minimal level of H3K4me3 was detected in the cd274 promoter 
region in normal pancreas in vivo (Figure 2D). The tumor cells exhibit the highest H4K4me3 
level in a region upstream of the transcription initiation region (Figure 2, A–D). ChIP sequencing 
of chromatin fragments from normal pancreas and orthotopic PANC02-H7 and UN-KC-6141 
tumor tissues revealed a cluster of H3K4me3 marks around the cd274transcription start site, and 
H3K4me3 marks are enriched in the cd274promoter region around -1000 to + 2000 in the tumor 
tissues (Figure 2E). 
 
Analysis of histone methyltransferases (HMTase) revealed that MLL1, one of the H3K4 
methylation-specific HMTases (27,28), is elevated in the orthotopic pancreatic tumor tissues 
both on the mRNA and the protein level (Figure 2F). PD-L1 is expressed in the normal pancreas 
tissues, albeit at a lower level (Figure 2F). PD-L1 transcript level is more elevated in the tumor 
cells than in the normal pancreatic tissues (Figure 2F). ChIP analysis revealed that MLL1 is 
directly associated with the cd274 promoter region in mouse pancreatic cancer cells in vitro and 
the orthotopic pancreatic tumor tissues in vivo (Figure 2G). Silencing MLL1 expression 
dramatically decreased H3K4me3 level in the CD274 promoter region (P = .03) and PD-L1 
mRNA level (P = .001) in human pancreatic cancer cells (Figure 2H). Similarly, silencing MLL1 
expression notably reduced the H3K4me3 level in the cd274 promoter region (P = .02) and 
statistically significantly downregulated the PD-L1 mRNA level (P = .002) in mouse pancreatic 
cancer cells (Figure 2I). PANC02-H7 cells were then transduced with scramble- and MLL1-
specific shRNA-coding lentivirus, and stable cells were selected. MLL1-specific shRNA 
downregulated MLL1 mRNA and protein level in the tumor cells (Supplementary Figure 1A, 
available online). Again, silencing MLL1 expression statistically significantly reduced the 
H3K4me3 level in the cd274promoter region (P = .004) and the PD-L1 expression level (P = 04) 
in the pancreatic cancer cells (Supplementary Figure 1A, available online). As a specificity 
control, an optimized mouse MLL1 full-length cDNA was made and cloned into a mammalian 
expression vector. This optimized MLL1-expressing plasmid was cotransfected with MLL1 
siRNA to the tumor cells. Analysis of the optimized MLL1 mRNA using optimized MLL1 
sequence-specific PCR primers indicates that it is resistant to WT MLL1-specific siRNA and 
that overexpression of this optimized MLL1 plasmid rescued WT MLL1 siRNA-mediated 
downregulation of PD-L1 as measured by PD-L1 mRNA level and protein level (Supplementary 
Figure 1, B and C, available online). 
 
MLL1 and PD-L1 Expression Patterns in Human Pancreatic Cancer Tissues 
 
Human pancreatic carcinoma specimens from 13 human pancreatic cancer patients were then 
analyzed by immunohistochemistry (IHC) using a human MLL1-specific antibody and a human 
PD-L1-specific antibody (29). Human tonsil and adrenal tumor tissues were used as positive 
controls. Epithelial cells surrounding the crypts in the tonsil tissue are PD-L1+ (Figure 3, A1a–c). 
Human adrenal tumor tissues exhibit two distinct PD-L1-staining patterns: 1) tumor cells with 
PD-L1 membrane staining and 2) tumor cells and leukocyte aggregate area with tumor cell 
membrane staining and both membrane and cytoplasmic staining in monocytes (Figure 3, A2a–
c). Approximately 20% to 30% of tumor cells in one of the tumor specimens are MLL1-positive 
(Supplementary Figure 2, A4). The majority of tumor cells (60%–90%) express MLL1 in the 
resting 11 tumor specimens (Figure 3, B1 and C1; Supplementary Figure 2, A1–A11, available 
online). MLL1 protein is primarily localized in the nucleus of the tumor cells. PD-L1 protein was 
detected in approximately 60% to 90% of tumor cells in all 13 tumor specimens (Figure 3, B2 
and C2; Supplementary Figure 2, B1–B11, available online). PDL1 protein was detected on the 
cell membrane and in the cytoplasms of almost all tumor cells. Consistent with the observation 
that PD-L1 protein is present in the majority of the tumor cells in all tumor specimens examined, 
flow cytometry analysis of 10 human pancreatic tumor cell lines revealed that nine of cell lines 
express high levels of PD-L1 (Figure 3B). All tumor cells uniformly express PD-L1, and almost 
all are PD-L1+ in nine of the 10 tumor cell lines (Figure 3C). Taken together, our data indicate 
that PD-L1 is uniformly expressed in murine and human pancreatic tumor cells cultured in vitro 
and is also abundantly expressed in orthotopic mouse pancreatic tumor cells and human 
pancreatic carcinoma cells in vivo. Analysis of mouse and human colon carcinoma and 
melanoma cells indicated that these two types of tumor cells are also uniformly PD-L1+, albeit at 
various levels (Supplementary Figure 3, A and B, available online). 
 
MLL1 and PD-L1 Expression in Pancreatic Cancer Cells 
 
We then made use of a recently identified HMTase inhibitor verticillin A that inhibits MLL1 
(30). Verticillin A inhibits MLL1 activity with an IC50 of 0.8 μM (Supplementary Figure 4A, 
available online). However, verticillin A does not inhibit global H3K4 methylation in human and 
mouse pancreatic cancer cells (Supplementary Figure 4B, available online). Interestingly, 
verticillin A statistically significantly decreased the H3K4me3 level in the cd274 promoter 
region in a dose-dependent manner in pancreatic tumor cells in vitro (P = .02) (Figure 4A). 
Consistent with the decreased H3K4me3 levels in the cd274promoter region, verticillin A 
dramatically decreased the PD-L1 mRNA level (P = .01) (Figure 4B) and the protein level 
(P = .007) (Figure 4C) in the tumor cells in vitro. Treatment of tumor-bearing mice with 
verticillin A also decreased the H3K4me3 level in the cd274 promoter region in the orthotopic 
tumor tissues (P = .04) (Figure 4D). PD-L1 mRNA level (P = .02) (Figure 4E) and protein level 
(P < .001) (Figure 4F) were also statistically significantly decreased in the orthotopic tumor 
tissues in vivo. 
 
Chaetocin is a potent HMTase inhibitor (31). Interestingly, chaetocin also exhibits potent 
inhibitory activity for MLL1 (Figure 5A). Treatment of human pancreatic cancer cells with 
chaetocin statistically significantly decreased the H3K4me3 level in the CD274 promoter region 
(P = .002) (Figure 5B). Consistent with decreased H3K4me3 level, PD-L1 protein level is 
statistically remarkably decreased in chaetocin-treated human pancreatic cancer cells (P < .001) 
(Figure 5C). Although chaetocin inhibits SUV39H1 and SUV39H2, HMTases that mediate 
H3K9me3 (31), the H3K9me3 level is low in the CD274 promoter region in human pancreatic 
cancer cells (Figure 5D). Conversely, overexpression of MLL1 increased MLL1 mRNA level, 
resulting in increased PD-L1 mRNA and protein levels in both PANC02-H7 and UN-KC-6141 
cells (P < .01) (Supplementary Figure 5, available online). 
 
 
Figure 3. MLL1 and PD-L1 protein levels in human pancreatic carcinoma 
cells. A) Immunohistochemical staining of human tissues. A1a and b) Human tonsil 
tissues were stained with anti-PD-L1 antibody. Shown are low (A1a) and high 
magnification (A1b) images of the stained tonsil tissue. A1a) The yellow arrows indicate 
PD-L1+ cells, the black arrow points to crypts, and green arrows point to lymphoid 
cells. A1b) The yellow arrows indicate PD-L1+ epithelial cells surrounding the 
crypt. A1c)Negative staining without anti-PD-L1 antibody. A2a–c) Human adrenal tumor 
tissues were stained with anti-human PD-L1 antibody. Shown are low (A2a) and high 
magnification (A2b and c) images of the stained adrenal tumor tissue. A2a) The yellow 
arrow indicates tumor cells, and the black arrowindicates tumor cells and leukocytes 
aggregate area. A2b) The yellow arrow indicates PD-L1+ tumor cells. A2c) The yellow 
arrow indicates PD-L1+ tumor cells, and the black arrows point to PD-
L1+monocytes. B1a and b and C1a and b) Two human pancreatic adenocarcinoma 
specimens were stained with anti-MLL1 antibody. Shown are low (B1a and C1a) and 
high magnification (B1b and C1b) images of the stained tumor tissues. Red 
arrows indicate MLL1+ tumor cells. B2a and b and C2a and b) The two human 
pancreatic adenocarcinoma specimens as shown in (B1 and C1) were stained with anti-
PD-L1 antibody. Shown are low (B2a and C2a) and high magnification (B2b and 
C2b) images of the stained tumor tissues. Yellow arrows indicate PD-L1+ tumor 
cells. Pink arrows in (B2b and C2b) indicate PD-L1 protein staining in both cell 
membrane and cytoplasm. MLL1- and PD-L1-specific staining is indicated by brown 
color, and nuclei were counterstained with hematoxylin in blue. B) Ten human 
pancreatic cancer cell lines were stained with IgG isotype control and PD-L1-specific 
monoclonal antibody, respectively, and analyzed for PD-L1 protein level by flow 
cytometry. C) Quantification of PD-L1 protein levels on human pancreatic cancer cell 
surface. The mean fluorescent intensity of PD-L1 protein as analyzed in (B) were 
quantified and presented. Column: mean; bar: SD. Scale bar (redline at the bottom 
left) = 50 μm. 
 
 
 
Figure 4. Function of MLL1 in regulation of PD-L1 expression through H3K4me3. A) PANC02-H7 cells were treated with verticillin 
A at the indicated doses for two days and analyzed by chromatin immunoprecipitation (ChIP) for H3K4me3 level in the ChIP 4 region 
of the cd274 promoter region. B)The untreated and verticillin A–treated (50 nM) PANC02-H7 cells as shown in (A) were analyzed for 
PD-L1 mRNA levels by quantitative polymerase chain reaction (qPCR). C) The untreated and verticillin A–treated (50 nM) PANC02-
H7 cells as shown in (A) were stained with PD-L1-specific monoclonal antibody (MAb) and analyzed by flow cytometry. PD-L1 
protein mean fluorescent intensity (MFI) is presented at the right. D) PANC02-H7 tumor-bearing mice (n = 5) were treated with 
verticillin A at 0.5 mg/kg body weight once every two days for 10 days, and the tumor tissues were analyzed by ChIP for H3K4me3 
level as in (A). The H3K4me3 level is normalized to input. E) The orthotopic PANC02-H7 tumor tissues from untreated and 
verticillin A–treated mice (n = 5) were analyzed for PD-L1 mRNA levels by qPCR. F) Tumor cells from untreated and verticillin A–
treated mice were stained with PD-L1-specific MAb and analyzed by flow cytometry. PD-L1 protein MFI is presented at the right. 
All statistical t tests were two-sided. ChIP = chromatin immunoprecipitation; MFI = mean fluorescent intensity; qPCR = quantitative 
polymerase chain reaction. 
 
 
Figure 5. Function of MLL1 in regulation of H3K4me3 in 
the CD274 promoter and PD-L1 expression in human pancreatic 
cancer cells. A) Chaetocin is a potent MLL1 inhibitor. Chaetocin 
was tested in a 10-dose IC50 mode with threefold serial dilutions 
using 3H-S-adenosyl-methionine as substrate with MLL1 
recombinant protein complex. The enzyme activity was then 
analyzed and plotted against chaetocin concentrations. IC50 was 
calculated using the Graphpad Prism program. B) PANC10.05 
cells were treated with chaetocin (50 nM) for two days and 
analyzed with H3K4me3-specific monoclonal antibody (MAb) by 
chromatin immunoprecipitation (ChIP). The ChIP DNA was 
amplified using ChIP primer 4. The relative H3K4me3 level was 
normalized to input DNA and analyzed by two-
sided t test. C) PANC10.05 cells were treated with chaetocin at the 
indicated doses for two days, stained with PD-L1-specific MAb, 
and analyzed by flow cytometry. The PD-L1 protein mean 
fluorescent intensity is presented at the right panel. Column: 
mean; bar: SD. D) H3K9me3 is not enriched in 
the CD274promoter region in human pancreatic cancer cells. 
PANC10.05 cells were analyzed by ChIP with H3K9me3-specific 
MAb and polymerase chain reaction primers. All statistical t tests 
were two-sided. ChIP = chromatin immunoprecipitation; mAb = 
monoclonal antibody. 
Role of FasL in Suppression of Pancreatic Tumor Growth In Vivo 
 
The Fas-mediated apoptosis pathway plays a key role in host cancer immune surveillance against 
spontaneous B lymphoma and colon carcinoma (22,32). In addition to H3K4me3, verticillin A 
also targets H3K9me3 to increase Fas expression in human colon cancer cells (30). PANC02-H7 
and UN-KC-6141 cells were then surgically transplanted to the pancreas of WT and faslgld mice. 
Analysis of tumor volume and tumor weight indicates that pancreatic tumors grew statistically 
dramatically faster in the faslgld mice than in the WT control mice in both tumor models 
(P = .03–.001) (Figure 6, A and E). Fas receptor is weakly expressed in both tumor cell lines in 
vitro, but is dramatically high in both orthotopic tumors in vivo (Figure 6, B and F). Analysis of 
tumor-infiltrating CTLs revealed that an average of 66.7% of tumor-infiltrating CTLs in the 
PANC02-H7 tumors and an average of 42.6% in the UN-KC-6141 tumors are FasL+ (Figure 6, C 
and G) in WT mice, whereas only a small fraction of CTLs in the spleen, LNs, and blood are 
FasL+ (Figure 6, C, D, G, and H). These observations suggest that the FasL of the host CTLs 
plays a key role in the suppression of pancreatic cancer development in vivo. 
 
Pharmacological Inhibition of HMTase and Anti-PD-L1 Immunotherapy Efficacy 
 
We then reasoned that verticillin A downregulates PD-L1 expression to decrease the threshold of 
anti-PD-L1 MAb dose and thereby augments the efficacy of anti-PD-L1 immunotherapy. To test 
the hypothesis, PANC02-H7 and UN-KC-6141 tumor-bearing mice were treated with verticillin 
A and anti-PD-L1 MAb, either alone or in combination. Although verticillin A and anti-PD-L1 
therapy alone suppressed tumor growth at the dose used, verticillin A statistically significantly 
increased the efficacy of anti-PD-L1 Mab in suppression of PANC02-H7 tumors as measured by 
tumor weight (P = .003–<.001) (Figure 7A). In the UN-KC-6141 tumor model, verticillin A and 
anti-PD-L1 exhibited additive effects in the suppression of tumor growth, and the combined 
treatment almost eradicated the established tumors (Figure 7B). At the functional level, 
verticillin A and anti-PD-L1 monotherapies decreased tumor cell proliferation and increased 
tumor cell apoptosis (Figure 7C). However, consistent with the greater degree of tumor growth 
inhibition, verticillin A statistically significantly increased the efficacy of anti-PD-L1 therapy in 
the suppression of tumor cell proliferation (P < .001) and in the induction of tumor cell apoptosis 
(P < .001) in vivo (Figure 7D). We also test the effects of verticillin A on the efficacy of anti-
PD-1 immunotherapy in the UN-KC-6141 tumor model. Both verticillin A and anti-PD-1 MAb 
remarkably suppressed the established tumor growth (Supplementary Figure 6, A and B, 
available online). However, verticillin A further statistically significantly improved the efficacy 
of anti-PD-1 immunotherapy as measured by decreased tumor weight (P = .05) (Supplementary 
Figure 6, A and B, available online). Taken together, our data indicate that targeting MLL1 can 
effectively enhance the efficacy of anti-PD-L1/PD-1 immunotherapy to suppress pancreatic 
tumor growth in vivo as measured by tumor weight. 
 
 
Figure 6. Role of the Fas-FasL system in suppression of pancreatic tumor growth in vivo. A) PANC02-H7 cells 
were surgically transplanted to the pancreas of wild-type (WT) C57BL/6 (n = 5) and faslgld (n = 5) mice. Shown are 
the established pancreatic tumors 15 days after tumor transplant. The tumor volume and tumor weight were analyzed 
by two-sided t test and are presented in the right panels. B) The cultured PANC02-H7 cells and PANC02-H7 tumor 
tissues from WT mice were analyzed for cell surface Fas protein level by flow cytometry. C) Cells were prepared 
from the indicated tissues from tumor-bearing WT mice as shown in (A), stained with 7-AAD, CD8-, and FasL-
specific monoclonal antibodies (MAbs), and analyzed by flow cytometry. The 7-AAD-CD8+ cells were gated and 
quantified for FasL+cells. D) Quantification of % CD8+FasL+ cells as shown in (C). E) UN-KC-6141 cells were 
surgically transplanted to the pancreas of WT C57BL/6 (n = 5) and faslgld (n = 5) mice. Shown are the established 
tumors 15 days after tumor transplant. The tumor volume and tumor weight were analyzed by two-sided t test and 
are presented in the right panels. F) The cultured UN-KC-6141 cells and UN-KC-6141 tumor tissues from WT 
mice were analyzed for cell surface Fas protein level by flow cytometry. G)Cells were prepared from the indicated 
tissues from tumor-bearing WT mice as shown in (E), stained with 7-AAD, CD8-, and FasL-specific MAbs and 
analyzed by flow cytometry. The 7-AAD-CD8+ cells were gated and quantified for FasL+ cells. H) Quantification of 
% CD8+FasL+ cells as shown in (G). LN = lymph node; WT = wild-type. 
 
Figure 7. Pharmacological inhibition of H3K4me3 and efficacy of anti-PD-L1 immunotherapy aganist pancreatic tumor growth in 
vivo. A) PANC02-H7 cells were surgically transplanted to wild-type (WT) mice. Five days later, tumor-bearing mice were randomly 
divided into four groups and treated with verticillin A (0.5 mg/kg body weight) and anti-PD-L1 (200 μg/mouse), either alone or in 
combination (n = 5) once every two days for 10 days. Shown are tumors of the different treated groups. Tumor volume and tumor 
weight were analyzed by two-sided t tests and are presented in the right panels. B) UN-KC-6141 cells were surgically transplanted to 
WT mice. Five days later, tumor-bearing mice were treated as in (A). Shown are tumors of the different treated groups. Tumor volume 
and tumor weight were analyzed by two-sided t tests and are presented in the right panels. C) The four groups of PANC02-H7 tumors 
as shown in (A) were sectioned and stained for Ki67 (left panel) and TUNEL (right panel). Shown are representative images of one 
of five tumors: a) control; b) verticillin A; c)anti-PD-L1 monoclonal antibody (MAb); d) verticillin A and anti-PD-L1 MAb. Scale 
bars in (C) are 20 μm, unless noted otherwise. D) Ki67+ (top panel) and TUNEL+ (bottom panel) cells in tumor tissues as shown 
in (C) were analyzed by two-sided t tests. Column: mean; bar: SD. 
 
 
 
Figure 8. Roles of FasL and T cells in enhancement of verticillin A and anti-PD-L1 immunotherapy. A) PANC02-H7 cells were 
surgically transplanted to faslgld mice. Five days later, tumor-bearing mice were randomly divided into two groups and treated with 
either solvent or verticillin A (0.5 mg/kg body weight) and anti-PD-L1 monoclonal antibody (MAb; 200 μg/mouse) once every two 
days for 10 days. Tumor volume and weight were analyzed by two-sided t tests (right panels). B) Comparison of tumor growth 
inhibition efficacy by combined verticillin A and anti-PD-L1 therapy in wild-type (WT) and faslgld mice. Tumor volume and weight in 
WT (as shown in Figure 6A) and faslgld (as shown in Figure 7A) mice treated with verticillin A and anti-PD-L1 MAb were compared 
with those of untreated mice and presented as % of control tumors. The difference between WT and Faslgld mice was analyzed by two-
sided t test. Column: mean; bar: SD. C) PANC02-H7 cells were surgically transplanted to WT mice. Five days later, tumor-bearing 
mice were randomly divided into four groups and treated with solvent (control, n = 5), anti-CD8 MAb (clone 2.43, 200 μg/mouse, 
n = 5), verticillin A (0.5 mg/kg body weight, n = 5) and anti-PD-L1 MAb (200 μg/mouse, n = 5), and verticillin A plus anti-PD-L1 plus 
anti-CD8 MAbs (n = 5) once every two days for 10 days. Tumor volume and tumor weight were analyzed by two-sided t tests and are 
presented in the right panels. D) UN-KC-6141 cells were surgically transplanted to WT mice. Five days later, tumor-bearing mice 
were treated as in (C). Tumor volume and tumor weight were analyzed by two-side t tests and are presented in the right panels. E 
and F) Tumor tissues from both PANC02-H7 (E) and UN-KC-6141 (F) tumor-bearing mice as shown in Figure 7, A and B, were 
collected after the indicated treatments and analyzed for CD8 and IFNγ mRNA levels by quantitative polymerase chain reaction. The 
differences between control and treatment group were analyzed by two-sided t tests. Column: mean; bar: SD. WT = wild-type. 
Verticillin A and Efficacy of Anti-PD-L1 Immunotherapy in FasL- and CTL-Deficient Tumor 
Microenvironment 
 
To determine whether the greater tumor suppression efficacy of combined verticillin A and anti-
PD-L1 immunotherapy depends on FasL and CTLs, PANC02-H7 cells were transplanted to 
pancreas of faslgld mice. The tumor-bearing mice were then treated with verticillin A and anti-
PD-L1 MAb. Although combined verticillin A and anti-PD-L1 MAb also noticeably inhibited 
tumor growth (Figure 8, A and B), the degree of tumor growth suppression is statistically 
significantly higher in WT mice (Figure 7, A and B) than in the faslgld mice (P = .02–<.001) 
(Figure 8, A and B). To further determine the role of CTLs in pancreatic tumor growth and anti-
PD-L1 immunotherapy efficacy, tumor-bearing mice were treated with a CD8+ T cell 
neutralization Mab, verticillin A + anti-PD-L1 MAb, or verticillin A + anti-PD-L1 Mab + 
CD8+ T cell neutralization Mab. Neutralizing CD8+ T cells markedly increased the growth rate 
of both PANC02-H7 and UN-KC-6141 tumors (P = .03–<.001) (Figure 8, C and D). 
Neutralizing CD8+ T cells also statistically significantly diminished the efficacy of combined 
verticillin A and anti-PD-L1 immunotherapy in PANC02-H7 and UN-KC-6141 tumor models as 
measured by tumor volume and weight (P= .37–.99) (Figure 8, C and D). Analysis of tumor 
tissues revealed that verticillin A further increased anti-PD-L1 Mab-induced CD8+ CTL tumor 
infiltration (P = .006–<.001) in both PANC02-H7 and UN-KC-6141 tumors and CTL activation 
as measured by IFNγ level in PANC02-H7 tumors (P = .02) in vivo (Figure 8, E and F). These 
observations suggest that pancreatic tumor growth control in vivo and anti-PD-L1 
immunotherapy efficacy depend on FasL and CTLs. 
 
Discussion 
 
H3K4 methylation in mammalian cells is catalyzed by multiple HMTases (33). Homozygous 
MLL SET-domain knockout mice have a relatively normal phenotype (34), and the histone 
methyltransferase activity of MLL1 seems dispensable for hematopoiesis (35). Furthermore, the 
effects of MLL1 deficiency on H3K4me3 and gene expression are minimal in mouse embryonic 
stem cells (36). However, MLL1 is essential for H3K4me3-dpendent Hox gene transcription 
activation in leukemia (27,28,37,38). Here we show that MLL1 is highly expressed in pancreatic 
cancer cells. We also show an H3K4me3 cluster present in the cd274 promoter region flanking 
the transcription start site in a normal mouse pancreas. However, H3K4me3 level is dramatically 
upregulated in the cd274 promoter region in pancreatic tumor tissues in vivo. We further show 
that inhibition of MLL1 activity or silencing of MLL1 expression decreases H3K4me3 level in 
the CD274 promoter region and downregulates PD-L1 expression in pancreatic tumor cells. 
Conversely, overexpression of MLL1 increased PD-L1 expression in pancreatic tumor cells. Our 
data thus extend MLL1 function to H3K4 methylation and PD-L1 transcription activation in 
pancreatic cancer cells. 
 
Immune suppression is a major limiting factor for cancer immunotherapy (39–41). Immune 
checkpoint blockade reverses immune suppression to activate tumor-reactive CTLs that directly 
target tumor cells for apoptosis (11,16,42). CTLs primarily use the perforin- and Fas-mediated 
effector mechanisms to induce tumor cell apoptosis. Recent studies have shown that immune 
suppressive cells selectively inhibit the perforin pathway of tumor-specific CTLs without 
downregulating CTL activation in vivo (43,44), suggesting that the Fas-mediated effector 
mechanism may be functional in the immune-suppressive tumor microenvironment. Indeed, it 
has been shown that the Fas-FasL axis represses spontaneous melanoma metastasis (45), and 
FasL-mediated immune surveillance by T cells is essential for the control of spontaneous B cell 
lymphomas (32). Here we demonstrated that pancreatic tumor–infiltrating CTLs are FasL+ and 
FasL plays a key role in the suppression of pancreatic cancer growth in vivo. Our data therefore 
reveal a key role of FasL of host CTLs in cancer immune surveillance against pancreatic cancer 
growth in vivo. 
 
One limitation of this study is that in addition to MLL1, verticillin A also inhibits five other 
HMTases (Supplementary Figure 4A, available online). Therefore, the specificity and toxicity of 
verticillin A as an epigenetic agent in cancer therapy remains to be further studied. Nevertheless, 
this proof of concept study indicates that epigenetic targeting of H3K4me3 is potentially 
effective in enhancing the efficacy of pancreatic cancer checkpoint immunotherapy. 
 
Pancreatic ductal adenocarcinoma is a highly aggressive cancer where prognosis has not been 
improved over the past few decades (46). Pancreatic cancer is also one of the few cancers that 
does not respond to checkpoint immunotherapy (14). It has been shown that the expression level 
of PD-L1 is positively correlated with the efficacy of anti-PD-1/PD-L1 immunotherapy (9). In 
the literature, it has been reported that PD-L1 expression is sparse in human pancreatic 
carcinoma tissues (42,47). However, we show here that human pancreatic carcinoma expresses 
abundant PD-L1 and the majority of tumor cells are PD-L1-positive. Furthermore, nine of the 10 
human pancreatic cancer cell lines are PD-L1-positive and no PD-L1- tumor cells are observed in 
these nine tumor cell lines. In this study, a specific and sensitive anti-PD-L1 MAb (clone 28-8) 
(29) was used, and this MAb has recently been approved by US Food and Drug Administration 
for detecting PD-L1 protein in human cancer patient tumor specimens. The discrepancy between 
our study and the reports in the literature might be due to the specificity and sensitivity of 
antibodies used, which requires further study. Nevertheless, the abundant PD-L1 protein level in 
human pancreatic cancer cells also suggests that the expression level of PD-L1 might be a 
determining factor of the PD-1/PD-L1 pathway-mediated cancer immune resistance against 
elimination by endogenous tumor-specific T cells in pancreatic cancer. This notion is supported 
by our observation that repression of MLL1-mediated PD-L1 expression with verticillin A 
statistically significantly increases the efficacy of anti-PD-L1/PD-1 immunotherapy against the 
established pancreatic cancer. Therefore, elevated PD-L1 expression levels in vivo might be a 
limiting factor for the poor response of pancreatic cancer to anti-PD-L1/PD-1 immunotherapy. 
However, although verticillin A and anti-PD-L1 alone exhibited statistically remarkable tumor 
suppressive activity, no synergistic effects were observed between these two agents, which is 
probably because of the fact that these two agents, when combined, almost eradicated the 
tumors. Further studies for various agent doses and treatment time are required. Nevertheless, 
our findings support the notion of combined epigenetic agents and immunotherapy to combat 
cancer (48). Specifically, the use of an epigenetic agent, such as an MLL1 inhibitor, to target 
H3K4me3 to decrease PD-L1 expression is potentially an effective approach to augment the 
efficacy of checkpoint blockade immunotherapy against deadly pancreatic cancer. 
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